Kelly Walton

List of Publications by Year
in descending order

11 papers	267 citations	1163117 8 h-index	1372567 10 g-index
11 all docs	11 docs citations	11 times ranked	470 citing authors

#	Article	IF	Citations
1	Targeting JAK2 reduces GVHD and xenograft rejection through regulation of T cell differentiation. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 1582-1587.	7.1	59
2	Decreased Suppression and Increased Phosphorylated STAT3 in Regulatory T Cells are Associated with Benefit from Adjuvant PD-1 Blockade in Resected Metastatic Melanoma. Clinical Cancer Research, 2018, 24, 6236-6247.	7.0	54
3	Targeting Aurora kinase A and JAK2 prevents GVHD while maintaining T _{reg} and antitumor CTL function. Science Translational Medicine, 2017, 9, .	12.4	48
4	IL-2 promotes early Treg reconstitution after allogeneic hematopoietic cell transplantation. Haematologica, 2017, 102, 948-957.	3.5	33
5	Human CD83-targeted chimeric antigen receptor T cells prevent and treat graft-versus-host disease. Journal of Clinical Investigation, 2020, 130, 4652-4662.	8.2	27
6	Inhibition of Human Dendritic Cell ER Stress Response Reduces T Cell Alloreactivity Yet Spares Donor Anti-tumor Immunity. Frontiers in Immunology, 2018, 9, 2887.	4.8	19
7	Metabolic reprogramming augments potency of human pSTAT3â€“inhibited iTregs to suppress alloreactivity. JCI Insight, 2020, 5, .	5.0	12
8	Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results. Clinical Cancer Research, 2021, 27, 2712-2722.	7.0	11
9	Dual JAK2/Aurora kinase A inhibition prevents human skin graft rejection by alloâ€inactivation and ILC2â€mediated tissue repair. American Journal of Transplantation, 2021, , .	4.7	3
10	Human CD83 Targeted Chimeric Antigen Receptor T Cell for the Prevention of Graft Versus Host Disease and Treatment of Myeloid Leukemia. Blood, 2019, 134, 196-196.	1.4	1
11	Biological and Clinical Impact of JAK2/mTOR Blockade in Gvhd Prevention: Preclinical and Phase I Trial Results. Blood, 2020, 136, 48-49.	1.4	0